ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 25,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $14.39, for a total value of $359,750.00. Following the transaction, the insider now owns 136,380 shares in the company, valued at approximately $1,962,508.20. This represents a 15.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Justin Chakma also recently made the following trade(s):

• On Monday, November 25th, Justin Chakma sold 32,814 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.00, for a total value of $459,396.00.

ARS Pharmaceuticals Stock Up 1.1 %

NASDAQ SPRY opened at $14.53 on Friday. The business has a 50 day simple moving average of $14.83 and a 200 day simple moving average of $11.99. ARS Pharmaceuticals, Inc. has a one year low of $4.65 and a one year high of $18.51.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Leerink Partners raised their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Buy” and an average target price of $24.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new stake in shares of ARS Pharmaceuticals during the first quarter worth about $60,000. Vanguard Group Inc. boosted its stake in ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after purchasing an additional 779,969 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in ARS Pharmaceuticals during the 1st quarter worth approximately $172,000. Jacobs Levy Equity Management Inc. raised its stake in shares of ARS Pharmaceuticals by 1,280.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock worth $2,838,000 after purchasing an additional 257,589 shares during the last quarter. Finally, RA Capital Management L.P. lifted its holdings in shares of ARS Pharmaceuticals by 14.8% in the first quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock valued at $110,999,000 after purchasing an additional 1,401,299 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.